M&M:针对具有随机延迟治疗效应的免疫疗法组序贯试验的Maxcombo检验最大持续时间设计
针对免疫疗法确认性临床试验中因个体生理条件异质性导致的随机延迟治疗效应,提出一种基于模拟的最大持续时间设计,采用稳健强效的Maxcombo检验用于组序贯试验。该设计通过模拟程序获得组序贯边界,并利用一维搜索确定所需最大样本量,其中另一模拟程序用于计算经验功效。模拟研究证明了组序贯边界的准确性及其对大样本最大样本量误设的稳健性,并揭示了在无差异零假设下对生存分布误设的中等敏感性。
要点
- 随机延迟治疗效应下,延迟时间难以从早期数据准确估计,阻碍最有效加权对数秩检验的指定。
- 提出基于模拟的最大持续时间设计,采用稳健强效的Maxcombo检验用于组序贯试验。
- 模拟研究证明了组序贯边界的准确性及对大样本最大样本量误设的稳健性。
核心结论
- 提出的基于模拟的最大持续时间设计结合Maxcombo检验,在随机延迟治疗效应下具有稳健的功效。
研究设计与样本
- 基于模拟的最大持续时间设计,用于具有随机延迟治疗效应的免疫疗法组序贯试验。
- 通过模拟程序获得组序贯边界,并利用一维搜索确定所需最大样本量,其中另一模拟程序用于计算经验功效。
主要发现
- 模拟研究证明了组序贯边界的准确性及其对大样本最大样本量误设的稳健性。
- 模拟研究揭示了在无差异零假设下对生存分布误设的中等敏感性。
- 研究调查了在「劣效」零假设下I类错误率是否会膨胀。
- 研究评估了Maxcombo检验与组分加权对数秩检验之间对不同延迟时间分布的经验功效稳健性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A random delayed treatment effect is expected in a confirmatory clinical trial for an immunotherapy due to the individual heterogeneity of physiological conditions. For this reason, the delay time will be assumed to follow a continuous distribution that is difficult to estimate accurately based on the early-phase data, which hinders the specification of the most powerful weighted log-rank test. Therefore, we propose a simulation-based maximum duration design with a robustly powerful Maxcombo test for a group sequential trial for the immunotherapy with the random delayed treatment effect. The design obtains the group sequential boundaries by a simulation procedure and determines the required maximum sample size using a one-dimensional search in which another simulation procedure is used to calculate empirical power. The simulation researches proved the accuracy of the group sequential boundaries and their robustness against the misspecified maximum sample sizes for large samples and revealed their moderate sensitivity against the misspecified survival distributions under the null hypothesis of no difference. The studies investigated whether the type I error rate would inflate under the "inferior" null hypothesis and evaluated the robustness against different distributions of the delay time in terms of the empirical power among the Maxcombo tests and component weighted log-rank tests.
引用
- Li B, Su L, Ye Y, et al. M&M: A maximum duration design with the Maxcombo test for a group sequential trial of an immunotherapy with a random delayed treatment effect. Stat Med. 2021. PMID: 34783047. doi:10.1002/sim.9251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。